Shantel
Key Takeaways:
- Invitae, a prominent medical genetics company, has announced the appointment of Robert Dickey as its interim Chief Financial Officer (CFO). Dickey’s extensive financial expertise and leadership experience are poised to guide the company’s financial strategies.
- Christine Gorjanc, who previously served as interim CFO, will transition to her role as Chair of the Audit Committee of the Board of Directors, collaborating with Dickey for a seamless transition.
- Dickey’s career spanning over 25 years as a CFO and in other C-level and board positions across life sciences and medical device companies underscores his ability to navigate complex financial landscapes.
About Invitae and Robert Dickey’s Appointment:
Invitae, a trusted name in the medical genetics field, has welcomed Robert Dickey as its interim CFO. This strategic appointment reflects Invitae’s dedication to strong financial leadership and sound decision-making. Robert Dickey’s illustrious career spanning over 25 years in various financial leadership roles positions him as a valuable addition to Invitae’s executive team.
Christine Gorjanc, who previously assumed the role of interim CFO in June 2023, will transition back to her prior position as Chair of the Audit Committee of the Board of Directors and a member of the Compensation Committee. Gorjanc will collaborate with Robert Dickey and the executive leadership team to ensure a seamless handover. She will also continue to contribute to Invitae’s search for a permanent CFO.
A Smooth Transition with Leadership Expertise:
Ken Knight, President and CEO of Invitae, expresses gratitude for Gorjanc’s willingness to step in as interim CFO and facilitate the selection of the right candidate for both short-term and long-term transitions. Robert Dickey’s extensive experience in private and public company financial leadership roles aligns with Invitae’s requirements for an interim CFO. Dickey’s proficiency in managing interim finance and permanent board-level positions with life science companies makes him an ideal choice. Knight states, “We are pleased to have identified an executive with his track record and financial acumen.”
Robert Dickey’s exceptional financial acumen is reflected in his more than 25 years of experience as a CFO and in other C-level and board positions within life sciences and medical device companies. His comprehensive knowledge spans all stages of the corporate lifecycle, from start-ups to high growth and turnarounds, including interactions with directors, shareholders, and the investment community.
A Diverse Background and Proven Track Record:
Dickey’s career includes 18 years in investment banking, primarily at Lehman Brothers, with expertise in M&A and capital markets transactions. As a part-time or interim CFO, he has consulted with over 10 companies in the life sciences space. Currently, Dickey serves as a member of the Board of Directors at companies such as AngioGenex, SFA Therapeutics, and GSNO Therapeutics. His educational background includes an MBA from The Wharton School, University of Pennsylvania, and an AB from Princeton University.
Christine Gorjanc’s Contribution and Future Growth:
Christine Gorjanc, transitioning to her role as Chair of the Audit Committee of the Board of Directors, reflects on her interim CFO role. She expresses confidence in Robert Dickey’s skills and experience, emphasizing the strengthened growth prospects for Invitae’s finance team under his guidance.
About Invitae’s Mission and Vision:
Invitae, a leading medical genetics company, operates with the mission of delivering timely genetic information to millions of patients and their providers. Leveraging digital technology, Invitae aims to provide accurate and actionable answers that empower medical decision-making for individuals and families. The company’s dedication to data and research drives its commitment to integrate comprehensive genetic information into mainstream medicine, thereby improving healthcare for a global population.
Conclusion: Navigating the Future with Financial Expertise:
Robert Dickey’s appointment as interim CFO at Invitae marks a pivotal step in strengthening the company’s financial leadership and strategies. With his extensive experience and diverse background across the finance sector, Dickey’s role is poised to guide Invitae through intricate financial landscapes. His expertise will contribute to optimizing business performance, fostering growth, and aligning financial strategies with the company’s mission. As Invitae continues to pioneer advancements in medical genetics, Robert Dickey’s leadership is set to play a key role in shaping the company’s path to a successful and impactful future.
